INTRODUCTION {#s1}
============

In the United States, there are estimated 13430 new cases diagnosed with laryngeal cancer in 2016 and laryngeal squamous cell carcinoma (LSCC) accounts for the vast majority of all laryngeal malignancies \[[@R1], [@R2]\]. In patients with LSCC, particularly for supraglottic area with abundant lymphatic network, there is a relatively high incidence of macro- or micrometastases, and involvement of even one lymph node might lead to a 50% reduction in survival time \[[@R3], [@R4]\]. Currently it's hard to detect these micrometastases by non-invasive methods \[[@R5], [@R6]\]. As a result, NCCN guideline recommends neck dissection for LSCC patients who are at risk for occult lymph node metastases in order to examine and remove the potential nodal focus \[[@R7]\]. Besides, neck dissection could also determine the necessity of adjuvant therapy and provide important predictive and prognostic information like lymph node ratio (LNR), which was defined as the number of pathologically positive nodes divided by the total counts of examined lymph nodes.

Integrating information on regionally metastatic burden with the extent of neck dissection, prognostic value of LNR for LSCC patients has been verified by several previous studies with large sample size \[[@R8]--[@R11]\]. However, AJCC N staging only provides information on maximal size, number and laterality of metastatic lymph nodes (Figure [1](#F1){ref-type="fig"}). Therefore, LNR can be used as a supplementary factor for N staging to describe lymph node status. In addition, AJCC T classification for laryngeal cancer was merely based on range of tumor invasion, combination of T staging and tumor size is also likely to better reflect tumor status from different aspects.

![American Joint Committee on Cancer (AJCC) N staging for laryngeal cancer\
LN is short for lymph node.](oncotarget-08-29722-g001){#F1}

There is a growing trend to use nomogram for cancer prognosis, specific nomograms have been successfully built for estimating survival, recurrence or local control for many cancer types \[[@R12]--[@R15]\]. Egelmeer et al have constructed nomograms for laryngeal cancer patients, however, the patients enrolled in that study only included patients treated with radiotherapy alone and whether those patients underwent neck dissection was unclear \[[@R16]\]. To the best of our knowledge, for LSCC patients, especially for those who underwent neck dissection, nomograms which make full use of available prognostic factors to predict survival have not been reported yet. Therefore in this study, we aimed to develop more practical and effective models for estimating OS and CSS for LSCC patients treated with neck dissection, in order to assist clinicians in predicting LSCC patient's individualized survival.

RESULTS {#s2}
=======

Patient baseline characteristics {#s2_1}
--------------------------------

A total of 2752 LSCC patients treated with neck dissection diagnosed between 1988 and 2008 were identified from Surveillance, Epidemiology, and End Results (SEER) database. We randomly allocated 2477 patients into the training cohort and other 275 in the validation cohort.

For the training cohort, the median follow-up time until censoring or death was 58 months (Range: 1--311 months) and the median age was 60 years old (Range: 24--96). Of these 2477 patients in the training cohort, 79.7% were male and 73.5% were white. We also observed that primary tumor in 57.3% of patients who received neck dissection arose from supraglottis, 53% were staged N0 while more than 60% were staged T3 and T4. Besides of neck dissection, 33.1% of enrolled patients received only cancer-directed surgery (30.3%) or only radiotherapy (2.8%) while the others (66.9%) underwent both of the treatment modalities. (Note: information on chemotherapy was not accessible in SEER database.) Results of neck dissection showed that the median of node examination counts was 25 (Range: 1--89) and the median of LNR was 0.019 (Range: 0--1), respectively. By the cutoff date of follow-up, 1159 patients (46.8%) had died from primary cancer and 612 (28.7%) died from other causes (Table [1](#T1){ref-type="table"}).

###### Baseline demographics and clinical characteristics of patients

  Characteristic                   All patients      Training cohort   Validation cohort                
  -------------------------------- ----------------- ----------------- ------------------- ------ ----- ------
  **Categorical variables**                                                                             
  Gender                                                                                                
   Female                          569               20.7              503                 20.3   66    24.0
   Male                            2183              79.3              1974                79.7   209   76.0
  **Race**                                                                                              
   White                           2019              73.4              1820                73.5   199   72.4
   Black                           617               22.4              547                 22.1   70    25.5
   Other^1^                        116               4.2               110                 4.4    6     2.2
  **Marital status**                                                                                    
   Married                         1380              50.1              1254                50.6   126   45.8
   Unmarried^2^                    1372              49.9              1223                49.4   149   54.2
  **Grade**                                                                                             
   Well differentiated             257               9.3               237                 9.6    20    7.3
   Moderately differentiated       1568              57.0              1426                57.6   142   51.6
   Poorly differentiated           888               32.3              794                 32.1   94    34.2
   Undifferentiated                39                1.4               20                  0.8    19    6.9
  **Site**                                                                                              
   Glottis                         855               31.1              773                 31.2   82    29.8
   Supraglottis                    1576              57.3              1418                57.2   158   57.5
   Subglottis                      93                3.4               84                  3.4    9     3.3
   Overlapping lesion              228               8.3               202                 8.2    26    9.5
  **Cancer-directed surgery**                                                                           
   No cancer-directed surgery      85                3.1               70                  2.8    15    5.5
   Local excision/destruction^3^   459               16.7              403                 16.3   56    20.4
   Total/Radical laryngectomy      2208              80.2              2004                80.9   204   74.2
  **Radiotherapy**                                                                                      
   No radiotherapy                 838               30.5              751                 30.3   87    31.6
   Receive radiotherapy            1914              69.5              1726                69.7   188   68.4
  **AJCC T status**                                                                                     
   T1                              322               11.7              288                 11.6   34    12.4
   T2                              755               27.4              700                 28.3   55    20.0
   T3                              404               14.7              346                 14.0   58    21.1
   T4a                             1175              42.7              1049                42.3   126   45.8
   T4b                             98                3.6               94                  3.8    4     1.5
  **AJCC N status**                                                                                     
   N0                              1300              47.2              1165                47.0   135   49.1
   N1                              420               15.3              372                 15.0   48    17.5
   N2a                             119               4.3               108                 4.4    11    4.0
   N2b                             573               20.8              534                 21.6   39    14.2
   N2c                             292               10.6              255                 10.3   37    13.5
   N3                              48                1.7               43                  1.7    5     1.8
  **AJCC M status**                                                                                     
   M0                              2691              97.8              2424                97.9   267   97.1
   M1                              61                2.2               53                  2.1    8     2.9
  **Continuous variables**                                                                              
  **Age at diagnosis**                                                                                  
   Median (Range)                  60 (24--96)       60 (24--96)       60 (25--85)                      
  **Tumor size (cm)**                                                                                   
   Median (Range)                  3.0 (0.1--23.0)   3.0 (0.1--23.0)   3.1 (0.2--10.0)                  
  **Number of LN examined**                                                                             
   Median (Range)                  25 (1--89)        25 (1--89)        27 (1--89)                       
  **Number of positive LNs**                                                                            
   Median (Range)                  1 (0--58)         1 (0--58)         1 (0--17)                        
  **Lymph node ratio**                                                                                  
   Median (Range)                  0.019 (0--1)      0.019 (0--1)      0.017 (0--1)                     

^1^Including American Indian/Alaska Native, Asian/Pacific Islander.

^2^Including patients who are never married, divorced, separated or widowed.

^3^Local destruction includes photodynamic therapy, electrocautery, cryosurgery, laser ablation, etc.

SEER 1988--2008.

Clinicopathologic characteristics of the validation cohort were also listed in Table [1](#T1){ref-type="table"}. Follow-up time ranged from 1 to 189 months (Median: 50) and 205 (74.5%) patients had died before the last follow-up, in which 132 (48.0%) were due to cancer.

Optimal cutoff values of LNR and Tumor size {#s2_2}
-------------------------------------------

In order to construct nomograms, we need to stratify the continuous variables in Table [1](#T1){ref-type="table"} into several categories. X-tile program, a practical tool for cut-point optimization, was used to determine the optimal cutoff values for tumor size and LNR by the minimal *P*-value approach \[[@R17]\].

Just as the method of Imre's and Ryu's studies, when calculating cutoff values for LNR, we only included patients with positive lymph nodes (N+) \[[@R18], [@R19]\]. Based on overall survival, the program identified optimal LNR cutoff point for node-positive patients as 0.14, the optimal tumor size cutoffs for the entire training cohort (including both node-negative and node-positive patients) were 3.0 and 4.0 cm (Figures [2 and 3](#F2){ref-type="fig"}). While based on cancer-specific survival which was another primary endpoint of our interest, X-tile identified optimal LNR cut-point for node-positive patients as 0.12, while the optimal tumor size cutoffs for the entire cohort were 3.0 and 3.9 cm ([Supplementary Figures 1 and 2](#SD1){ref-type="supplementary-material"}). For the purpose of a unified standard, we adopted optimal cutoffs of LNR and tumor size based on OS, as X-tile utilized Kaplan-Meier method for analysis, which was more suitable for estimating overall survival.

![X-tile analysis identifying optimal LNR cutoffs based on OS\
X-tile analysis was conducted on patients with positive lymph nodes in the training cohort (*n* = 1312), these 1312 patients in the training cohort was equally divided into training (*n* = 656) and validation sets (*n* = 656). X-tile plots of training sets are shown in the left panels, the "lock" symbol in the left panel means optimal cutoffs have been determined, a histogram (middle panels) and a Kaplan-Meier plot (right panels) was performed based on these cutoffs. *P* values were determined by using the cut-point defined in the training set and applying it to the validation set. Optimal LNR cut-point was determined as 0.14 based on OS (χ2 = 55.675, *P \<* 0.001). As the X axis could only show one decimal place, so we added a text annotation "Cutoff value = 0.14" in the middle panel.](oncotarget-08-29722-g002){#F2}

![X-tile analysis identifying optimal tumor size cutoffs based on OS\
X-tile analysis was conducted on the training cohort of our study (*n* = 2477), these 2477 patients in the training cohort was equally divided into training (*n* = 1238) and validation sets (*n* = 1239). X-tile plots of training sets are shown in the left panels, the "lock" symbol in the left panel means optimal cutoffs have been determined, a histogram (middle panels) and a Kaplan-Meier plot (right panels) was performed based on these cutoffs. *P* values were determined by using the cut-point defined in the training set and applying it to the validation set. Optimal tumor size cut-points were identified as 30mm and 40mm based on OS (χ2 = 59.83, *P* \< 0.001).](oncotarget-08-29722-g003){#F3}

![Nomograms estimating 3- and 5-year (**A**) overall survival (**B**) cancer-specific survival of LSCC patients treated with neck dissection. Instructions of the nomograms: First, each characteristic of an individual patient is located on the corresponding axis, we can draw a vertical line from that variable to the points scale to obtain its point (or look up Table [6](#T6){ref-type="table"}). Second, we need to add up the points of each characteristic to obtain a total point, then draw a vertical line from the Total Points Scale to the 3- and 5-year OS or CSS scale to get the estimated probabilities of survival.](oncotarget-08-29722-g004){#F4}

Consequently, the entire training cohort was divided into ≤ 3 cm, 3.1--4 cm and \> 4 cm groups by tumor size. Those node-positive patients were divided into 0.01--0.14 group and \> 0.14 group by LNR. When combined with node-negative patients, the entire training cohort was divided into LNR = 0, LNR 0.01--0.14 and LNR \> 0.14 groups. Patients' age at diagnosis was also stratified by ten-year age groups. Table [2](#T2){ref-type="table"} summarized baseline information on age, LNR and tumor size after categorization.

###### Baseline information on age, tumor size and LNR after setting up optimal cutoff values

  Characteristic         All patients   Training cohort   Validation cohort                
  ---------------------- -------------- ----------------- ------------------- ------ ----- ------
  **Age at diagnosis**                                                                     
   \< 45                 190            6.9               171                 6.9    19    6.9
   45--54                617            22.4              560                 22.6   57    20.7
   55--64                1039           37.8              929                 37.5   110   40.0
   65--74                676            24.6              607                 24.5   69    25.1
   ≥ 75                  230            8.4               210                 8.5    20    7.3
  **Tumor size (cm)**                                                                      
   ≤ 3                   1475           53.6              1320                53.3   155   56.4
   3.1--4                701            25.5              637                 25.7   64    23.3
   \> 4                  576            20.9              520                 21.0   56    20.4
  **Lymph node ratio**                                                                     
   0                     1310           47.6              1175                47.4   135   49.1
   0.01--0.14            889            32.3              805                 32.5   84    30.5
   \> 0.14               553            20.1              497                 20.1   56    20.4

SEER 1988--2008.

Factors associated with OS in the training cohort {#s2_3}
-------------------------------------------------

Of the 2477 patients in the training cohort, in the univariate analysis, all the demographics and tumor characteristics in Table [1](#T1){ref-type="table"} were associated with OS (*P* \< 0.05) and no multicollinearity was observed among the variables (all VIFs \< 5). These variables were included in the multivariate Cox proportional hazards regression model. Furtherly in the multivariate analysis, all the included characteristics remained significant for OS according to Wald test (*P* \< 0.05) (Table [3](#T3){ref-type="table"}).

###### Univariate and multivariate analysis of overall survival in the training cohort

  Characteristic                Univariate analysis   Multivariate analysis              
  ----------------------------- --------------------- ----------------------- ---------- ----------
  **Age at diagnosis**          \< 0.001                                                 \< 0.001
   \< 45                                              0.314 (0.244--0.405)    \< 0.001   
   45--54                                             0.433 (0.361--0.520)    \< 0.001   
   55--64                                             0.556 (0.470--0.657)    \< 0.001   
   65--74                                             0.781 (0.659--0.926)    0.004      
   ≥75                                                Reference                          
  **Gender**                    \< 0.001                                                 0.038
   Female                                             Reference                          
   Male                                               1.132 (1.007--1.272)    0.038      
  **Race**                      0.020                                                    0.005
   White                                              Reference                          
   Black                                              1.125 (1.005--1.259)    0.040      
   Other                                              0.757 (0.597--0.959)    0.021      
  **Marital status**            \< 0.001                                                 \< 0.001
   Married                                            Reference                          
   Unmarried                                          1.294 (1.176--1.423)    \< 0.001   
  **Grade**                     \< 0.001                                                 0.043
   Well differentiated                                Reference                          
   Moderately differentiated                          1.020 (0.861--1.208)    0.804      
   Poorly differentiated                              1.134 (1.037--1.249)    0.015      
   Undifferentiated                                   1.685 (1.017--2.791)    0.043      
  **Site**                      0.011                                                    0.040
   Glottis                                            Reference                          
   Supraglottis                                       1.124 (0.936--1.351)    0.211      
   Subglottis                                         1.186 (0.992--1.417)    0.056      
   Overlapping lesion                                 1.301 (1.180--1.419)    \< 0.001   
  **Cancer-directed surgery**   \< 0.001                                                 \< 0.001
   No cancer-directed surgery                         Reference                          
   Local excision/destruction                         0.599 (0.444--0.808)    0.001      
   Total/Radical laryngectomy                         0.770 (0.581--1.020)    0.069      
  **Radiotherapy**              0.005                                                    \< 0.001
   No radiotherapy                                    Reference                          
   Receive radiotherapy                               0.790 (0.706--0.884)    \< 0.001   
  **AJCC T status**             \< 0.001                                                 0.031
   T1                                                 Reference                          
   T2                                                 1.124 (0.949--1.330)    0.175      
   T3                                                 1.154 (0.945--1.408)    0.161      
   T4a                                                1.288 (1.083--1.531)    0.004      
   T4b                                                1.338 (0.991--1.806)    0.057      
  **AJCC N status**             \< 0.001                                                 \< 0.001
   N0                                                 Reference                          
   N1                                                 1.222 (0.562--2.649)    0.612      
   N2a                                                1.732 (0.786--3.816)    0.173      
   N2b                                                1.554 (0.721--3.352)    0.261      
   N2c                                                1.969 (0.913--4.246)    0.084      
   N3                                                 2.044 (0.902--4.633)    0.087      
  **AJCC M status**                                                                      \< 0.001
   M0                                                 Reference                          
   M1                                                 1.931 (1.364--2.734)    \< 0.001   
  **Tumor size (cm)**           \< 0.001                                                 0.005
   ≤ 3                                                Reference                          
   3.1--4                                             1.171 (1.046--1.310)    0.006      
   \> 4                                               1.177 (1.041--1.331)    0.009      
  **Lymph node ratio**          \< 0.001                                                 \< 0.001
   0                                                  Reference                          
   0.01--0.14                                         1.137 (0.530--2.441)    0.741      
   \> 0.14                                            1.606 (0.750--3.439)    0.223      

Abbreviations: HR: Hazard Ratio; CI: Confidence Interval.

^1^Including American Indian/Alaska Native, Asian/Pacific Islander.

^2^Including patients who are never married, divorced, separated or widowed.

^3^Local destruction includes photodynamic therapy, electrocautery, cryosurgery, laser ablation, etc.

(*n* = 2477).

Cancer-specific mortality, competing risks and multivariate analysis for CSS {#s2_4}
----------------------------------------------------------------------------

Cumulative incidence function (CIF), which was an unbiased way for analyzing cause-specific incidence when competing risk exists, was used to estimate cancer-specific mortality (CSM) and deaths resulting from other causes (DROC), as appropriate. The 3- and 5-year cumulative incidences of cancer-specific mortality (CICSM) were 30.1% and 37.2%, respectively, and the 3- and 5-year cumulative incidences of DROC were 6.2% and 11.3%, respectively. Gray's test showed that all the variables, except race, proved to be associated with CSM (*P* \< 0.05). We also observed that in patients of each subgroup except those ≥ 75 years old, CSM estimated by Kaplan-Meier method was quite close to the results by CIF, indicating that the low incidence of competing risks played a very slight interfering role in the Kaplan-Meier estimates for CSS (Table [4](#T4){ref-type="table"}).

###### 3- and 5-year cumulative incidences of death in the training cohort

  Characteristic                Cumulative Incidence of CSM   CSM by Kaplan-Meier estimates   Cumulative Incidence of DROC                                   
  ----------------------------- ----------------------------- ------------------------------- ------------------------------ ------- ------- ------- ------- --------------
   **All patients**             30.1%                         37.2%                                                          31.1%   39.5%   6.2%    11.3%   
   **Age at diagnosis**                                                                       **\< 0.001**                                                   **\< 0.001**
   \< 45                        23.2%                         29.4%                                                          23.9%   30.4%   3.8%    6.8%    
   45--54                       27.6%                         33.9%                                                          28.1%   35.1%   3.4%    7.7%    
   55--64                       29.6%                         36.2%                                                          30.4%   37.9%   4.8%    9.1%    
   65--74                       32.6%                         41.2%                                                          34.1%   44.7%   8.7%    15.3%   
   ≥75                          37.7%                         46.3%                                                          40.9%   52.9%   15.4%   23.0%   
  **Gender**                                                                                  **0.035**                                                      **0.376**
   Female                       24.6%                         33.9%                                                          25.6%   36.3%   7.2%    9.8%    
   Male                         31.4%                         38.0%                                                          32.5%   40.2%   6.0%    11.7%   
  **Race**                                                                                    **0.160**                                                      **0.258**
   White                        29.4%                         36.4%                                                          30.4%   38.5%   6.4%    11.4%   
   Black                        31.9%                         40.0%                                                          33.4%   42.8%   6.8%    11.9%   
   Other                        31.5%                         37.2%                                                          31.9%   38.0%   1.9%    6.5%    
  **Marital status**                                                                          **0.008**                                                      **0.046**
   Married                      26.5%                         33.7%                                                          27.2%   35.5%   5.5%    10.0%   
   Unmarried                    33.7%                         40.8%                                                          35.2%   43.6%   7.1%    12.8%   
  **Grade**                                                                                   **\< 0.001**                                                   **0.018**
   Well differentiated          20.1%                         24.8%                                                          20.8%   26.3%   7.5%    14.4%   
   Moderately differentiated    28.1%                         35.6%                                                          29.0%   37.6%   5.5%    10.2%   
   Poorly differentiated        36.3%                         43.6%                                                          37.9%   46.7%   7.2%    12.2%   
   Undifferentiated             40.4%                         45.5%                                                          40.8%   48.2%   7.3%    22.3%   
  **Site**                                                                                    **0.016**                                                      **0.388**
   Glottis                      26.3%                         32.9%                                                          27.2%   34.8%   7.2%    11.4%   
   Supraglottis                 31.2%                         38.5%                                                          32.6%   41.2%   7.6%    12.0%   
   Subglottis                   33.8%                         40.3%                                                          33.9%   41.1%   3.6%    8.1%    
   Overlapping lesion           36.6%                         47.5%                                                          36.5%   48.5%   1.4%    8.4%    
  **Cancer-directed surgery**                                                                 **\< 0.001**                                                   **0.324**
   No cancer-directed surgery   46.2%                         57.9%                                                          47.4%   62.3%   5.9%    11.6%   
   Local excision/destruction   20.9%                         28.2%                                                          21.4%   29.5%   5.0%    8.3%    
   Total/Radical laryngectomy   31.3%                         38.3%                                                          32.5%   40.7%   6.6%    11.9%   
  **Radiotherapy**                                                                            **\< 0.001**                                                   **0.041**
   No radiotherapy              26.8%                         32.3%                                                          28.1%   34.6%   7.9%    13.5%   
   Receive radiotherapy         31.5%                         39.4%                                                          32.4%   41.5%   5.6%    10.4%   
  **AJCC T status**                                                                           **\< 0.001**                                                   **0.071**
   T1                           21.0%                         26.9%                                                          21.6%   28.3%   6.0%    9.5%    
   T2                           26.1%                         33.0%                                                          27.5%   35.7%   8.3%    13.9%   
   T3                           24.4%                         33.5%                                                          24.7%   35.0%   4.2%    9.3%    
   T4a                          34.9%                         41.8%                                                          36.1%   44.0%   5.8%    11.2%   
   T4b                          53.7%                         63.4%                                                          56.2%   67.1%   4.7%    6.9%    
  **AJCC N status**                                                                           **\< 0.001**                                                   **0.002**
   N0                           16.3%                         23.3%                                                          16.8%   24.2%   4.6%    10.0%   
   N1                           29.1%                         35.9%                                                          30.6%   38.8%   8.1%    14.6%   
   N2a                          42.2%                         48.8%                                                          46.4%   54.5%   11.2%   15.0%   
   N2b                          43.3%                         51.2%                                                          45.5%   54.9%   7.1%    11.4%   
   N2c                          55.7%                         64.1%                                                          59.5%   69.5%   7.1%    11.1%   
   N3                           51.7%                         63.3%                                                          54.5%   68.4%   8.9%    11.3%   
  **AJCC M status**                                                                           **\< 0.001**                                                   **0.187**
   M0                           29.3%                         36.5%                                                          30.3%   38.7%   6.3%    11.4%   
   M1                           67.7%                         71.6%                                                          72.7%   77.3%   6.9%    6.9%    
  **Tumor size (cm)**                                                                         **\< 0.001**                                                   **0.425**
   ≤ 3                          24.8%                         32.6%                                                          22.5%   31.0%   5.3%    10.2%   
   3.1--4                       33.3%                         39.9%                                                          30.7%   39.3%   7.1%    13.1%   
   \> 4                         39.5%                         45.7%                                                          41.5%   48.9%   7.9%    12.2%   
  **Lymph node ratio**                                                                        **\< 0.001**                                                   **\< 0.001**
   0                            16.5%                         23.5%                                                          17.0%   24.5%   4.6%    10.0%   
   0.01--0.14                   33.0%                         41.4%                                                          34.6%   44.0%   9.1%    14.2%   
   \> 0.14                      54.9%                         61.5%                                                          57.2%   65.1%   5.9%    9.8%    

Abbreviations: CSM: cancer-specific mortality; DROC: death resulting from other causes.

*P*\*: *P* value calculated by Gray's test.

(*n* = 2477).

Owing to the limited interference effect of competing risks, Cox proportional hazards model rather than sub-distribution competing risks model was used to conduct multivariate analysis for CSS and build nomograms (Reasons for choosing Cox model was discussed furtherly in Discussion section). Furtherly, all the significant variables in the univariate test in Table [4](#T4){ref-type="table"} were confirmed to be independent prognostic factors for CSS in multivariate analysis (Table [5](#T5){ref-type="table"}).

###### Multivariate analysis of cancer-specific survival in the training cohort

  Characteristic                Multivariate analysis              
  ----------------------------- ----------------------- ---------- --------------
  **Age at diagnosis**                                             **\< 0.001**
   \< 45                        0.448 (0.324--0.619)    \< 0.001   
   45--54                       0.612 (0.485--0.772)    \< 0.001   
   55--64                       0.712 (0.573--0.885)    0.002      
   65--74                       0.908 (0.726--1.134)    0.394      
   ≥75                          Reference                          
  **Gender**                                                       **0.046**
   Female                       Reference                          
   Male                         1.152 (1.005--1.326)    0.046      
  **Site**                                                         **0.041**
   Glottis                      Reference                          
   Supraglottis                 1.042 (0.829--1.309)    0.726      
   Subglottis                   1.058 (0.849--1.318)    0.617      
   Overlapping lesion           1.291 (1.174--1.420)    \< 0.001   
  **Marital status**                                               **0.001**
   Married                      Reference                          
   Unmarried                    1.214 (1.077--1.368)    0.001      
  **Grade**                                                        **0.036**
   Well differentiated          Reference                          
   Moderately differentiated    1.253 (0.979--1.602)    0.073      
   Poorly differentiated        1.385 (1.070--1.792)    0.013      
   Undifferentiated             1.730 (0.862--3.474)    0.123      
  **Cancer-directed surgery**                                      **0.005**
   No cancer-directed surgery   Reference                          
   Local excision/destruction   0.576 (0.406--0.817)    0.002      
   Total/Radical laryngectomy   0.706 (0.511--0.977)    0.035      
  **Radiotherapy**                                                 **0.001**
   No radiotherapy              Reference                          
   Receive radiotherapy         0.780 (0.674--0.902)    0.001      
  **AJCC T status**                                                **0.001**
   T1                           Reference                          
   T2                           1.205 (0.958--1.515)    0.111      
   T3                           1.388 (1.068--1.804)    0.014      
   T4a                          1.517 (1.202--1.914)    \< 0.001   
   T4b                          1.713 (1.191--2.466)    0.004      
  **AJCC N status**                                                **\< 0.001**
   N0                           Reference                          
   N1                           1.259 (0.502--3.155)    0.623      
   N2a                          2.128 (0.837--5.409)    0.113      
   N2b                          1.757 (0.706--4.373)    0.226      
   N2c                          2.414 (0.970--6.004)    0.058      
   N3                           2.375 (0.903--6.250)    0.081      
  **AJCC M status**                                                **\< 0.001**
   M0                           Reference                          
   M1                           2.054 (1.389--3.038)    \< 0.001   
  **Tumor size (cm)**                                              **0.045**
   ≤ 3                          Reference                          
   3.1--4                       1.099 (0.952--1.270)    0.198      
   \> 4                         1.191 (1.023--1.386)    0.025      
  Lymph node ratio                                                 **\< 0.001**
   0                            Reference                          
   0.01--0.14                   1.159 (0.469--2.862)    0.749      
   \> 0.14                      1.850 (0.751--4.555)    0.181      

Abbreviations: HR: Hazard Ratio; CI: Confidence Interval. (*n* = 2477).

Establishment and validation of the nomograms {#s2_5}
---------------------------------------------

By a backward stepwise method based on the smallest Akaike Information Criterion (AIC), all the significant factors in multivariate analysis were incorporated to develop nomograms predicting 3- and 5-year OS and CSS (Figure [4](#F4){ref-type="fig"}). Detailed scores of each nomogram predictor were presented in Table [6](#T6){ref-type="table"}.

![Internal calibration plots for (**A**) 3-year OS, (**B**) 5-year OS, (**C**) 3-year CSS, (**D**) 5-year CSS. The diagonal dashed line in each plot represents perfect match between nomogram prediction (x-axis) and actual observed survival (y-axis). The training cohort was divided into 10 groups with equal sample size for internal validation. Closer distances between the fit line and the diagonal line indicate higher prediction accuracy.](oncotarget-08-29722-g005){#F5}

###### Detailed scores of each predictor in the nomograms

  Characteristic                OS nomogram   CSS nomogram
  ----------------------------- ------------- --------------
  **Age at diagnosis**                        
   \< 45                        0.0           0.0
   45--54                       2.8           3.5
   55--64                       4.9           5.3
   65--74                       7.9           8.0
   ≥ 75                         10.0          9.1
  **Gender**                                  
   Female                       0.0           0.0
   Male                         1.1           1.6
  **Race**                                    
   White                        2.4           
   Black                        3.4           Not included
   Other                        0.0           
  **Marital status**                          
   Married                      0.0           0.0
   Unmarried                    2.2           2.2
  **Grade**                                   
   Well differentiated          0.0           0.0
   Moderately differentiated    0.2           2.5
   Poorly differentiated        1.1           3.7
   Undifferentiated             4.5           6.2
  **Site**                                    
   Glottis                      0.0           0.0
   Supraglottis                 1.0           0.5
   Subglottis                   1.5           0.6
   Overlapping lesion           2.3           2.9
  **Cancer-directed surgery**                 
   No cancer-directed surgery   4.4           6.3
   Local excision/destruction   0.0           0.0
   Total/Radical laryngectomy   2.2           2.3
  **Radiotherapy**                            
   No radiotherapy              2.1           2.8
   Receive radiotherapy         0.0           0.0
  **AJCC T status**                           
   T1                           0.0           0.0
   T2                           1.0           2.1
   T3                           1.2           3.7
   T4a                          2.2           4.7
   T4b                          2.5           6.1
  **AJCC N status**                           
   N0                           0.0           0.0
   N1                           1.7           2.6
   N2a                          4.8           8.6
   N2b                          3.8           6.4
   N2c                          5.9           10.0
   N3                           6.2           9.8
  **AJCC M status**                           
   M0                           0.0           0.0
   M1                           5.9           8.3
  **Tumor size (cm)**                         
   ≤ 3                          0.0           0.0
   3.1--4                       1.4           1.1
   \> 4                         1.5           2.0
  **Lymph node ratio**                        
   0                            0.0           0.0
   0.01--0.14                   1.1           1.7
   \> 0.14                      4.1           7.0

The nomograms were validated by bootstrap resampling internally and externally. Harrell's Concordance-indexes (C-index), as an indicator of predictive abilities, were compared among nomogram models, no-LNR models (including all the variables in the nomograms except LNR) and TNM models (including only TNM status). As shown in Table [7](#T7){ref-type="table"}, in the internal validation via training cohort, the nomogram models possessed higher C-indexes (OS: 0.713; CSS: 0.725) than no-LNR model (OS: 0.703; CSS: 0.713) and TNM model (OS: 0.667; CSS: 0.688). In the validation cohort for external validation, similarly, nomogram model (OS: 0.704; CSS: 0.709) still demonstrated superiority over no-LNR model (OS: 0.690; CSS: 0.693) and TNM model (OS: 0.658; CSS: 0.672). C-index and AIC of each model were presented in Table [7](#T7){ref-type="table"}. Internal and external calibration plots for OS and CSS also showed good agreement between nomogram prediction and observed outcomes (Figures [5 and 6](#F5){ref-type="fig"}).

###### Predictive ability of different prediction models

  Predicting models              Harrell's C-index      AIC        
  ------------------------------ ---------------------- ---------- --
  **Internal validation**        **Overall survival**              
  TNM classification             0.667                  26193.53   
  No-LNR model                   0.703                  25971.86   
  Nomogram model                 0.713                  25946.89   
  **Cancer-specific survival**                                     
  TNM classification             0.688                  16491.48   
  No-LNR model                   0.713                  16419.76   
  Nomogram model                 0.725                  16385.39   
  **External validation**        **Overall survival**              
  TNM classification             0.658                  6096.82    
  No-LNR model                   0.690                  6075.84    
  Nomogram model                 0.704                  6052.44    
  **Cancer-specific survival**                                     
  TNM classification             0.672                  3948.56    
  No-LNR model                   0.693                  3947.39    
  Nomogram model                 0.709                  3921.78    

Abbreviations: AIC: Akaike Information Criterion.

SEER 1988--2008.

![External calibration plots for (**A**) 3-year OS, (**B**) 5-year OS, (**C**) 3-year CSS, (**D**) 5-year CSS. The diagonal dashed line in each plot represents perfect match between nomogram prediction (X-axis) and actual observed survival (Y-axis). The validation cohort was divided into 10 groups with equal sample size for external validation. Closer distances between the fit line and the diagonal line indicate higher prediction accuracy.](oncotarget-08-29722-g006){#F6}

It's easy and comprehensible to predict survival by nomograms which possess a user-friendly interface. Based on an individual patient's information, we can look up Table [6](#T6){ref-type="table"} to obtain the point of each prognostic factor, and then add up the points and predict survival by the corresponding survival probabilities of the total points. Take this example, for a married 60 year-old white man, he was diagnosed with well-differentiated T4aN1M0 glottis squamous cell carcinoma with a primary tumor of 2.5 cm in greatest diameter, he didn't undergo cancer-directed surgery but received radiotherapy, neck dissection showed 5% of examined lymph nodes had signs of metastasis. In summary, he got 17.8 and 22.2 points in OS and CSS nomograms, respectively, corresponding to an estimated 56% 5-year OS rate and 65% 5-year CSS rate. In the same manner, we could also predict a relatively short-term 3-year survival rate with the nomograms.

DISCUSSION {#s3}
==========

Cancer prognosis has proved to be closely related to different aspects of factors, such as demographics, tumor characteristics and treatment conditions. AJCC TNM status, which has been the most widely used system for outcome estimation, however, is not sufficient to satisfy current need. Nomogram, considered to be a graphical depiction of prediction model, gives oncologists an opportunity to combine different tumor prognostic factors together, thus to help us assess the risk of failure more precisely \[[@R20], [@R21]\].

Regardless of surgery or radiotherapy as treatment for primary tumor, neck dissection is recommended for LSCC patients with potential node involvement \[[@R7]\]. LNR information obtained from neck dissection could also help improve our understanding of node metastasis in depth. Published nomograms developed in Ju's and Shen's studies focused on prognosis of squamous cell carcinoma of all sites of head and neck based on SEER database with large sample size, however, patients included in their studies didn't necessarily need to receive neck dissection thus information on LNR of these patients was not available to be incorporated into the nomograms. Moreover, as characteristics of tumors from different sites of head and neck may vary greatly, it might not be most appropriate to use the same predictive tool to estimate prognosis of different head and neck cancer. When we predicted survival of LSCC patients treated with neck dissection, for these reasons above, the nomograms in Ju's and Shen's researches were not able to achieve the best predictive performance \[[@R22], [@R23]\]. Consequently, in terms of necessity, we established more comprehensive nomograms to predict survival of LSCC patients who underwent neck dissection and they proved to be more accurate than previous models as well as conventional TNM staging systems. Since SEER program is comprised of 18 cancer registries covering thousands of hospitals and nearly 30% of total population across the nation, heterogeneity of the data allowed the models to be broadly used for decision-making in clinical practice.

Through univariate Log-rank test and multivariate Cox analysis, independent predictive factors for OS were identified. When we selected the variables to build nomograms, backward stepwise methods were used to determine the smallest AIC value in order to minimize the information loss. With regard to CSS, according to Fine and Gray, an overestimation of failure is expected due to the existing competing risks when Kaplan-Meier and Cox proportional hazards analysis were applied \[[@R24]\]. However, in the comparison between Kaplan-Meier estimates and the CIF means, very close CSM results suggested the relative low incidence of competing risks in our study might not be a critical consideration. In view of Cox models' high interpretability by nomogram and comparability with previous literatures, just as the method of Valentini's research and some other prior studies \[[@R25]--[@R27]\], we still adopted a multivariate Cox proportional hazards model for CSS analysis.

In our study, we validated some clinicopathological factors as important prognostic indicators for both OS and CSS in the multivariate analysis, including sociodemographic factors like age at diagnosis, gender, marital status; tumor characteristics such as primary site, grade, TNM status, tumor size and lymph node ratio; as well as treatment conditions like surgery and radiotherapy. As shown in our nomograms, age at diagnosis revealed strong impact on OS and CSS. In average, compared with a patient less than 45 years old, 5-year OS and CSS rates were reduced by 35% and 20% for those over 75, even if they had the same exposure to other risk factors. Age was also proved to be an important predictive and prognostic factor in some previous studies. Ampil et al confirmed that age was a prognostic factor in T4 laryngeal carcinoma \[[@R28]\], Kowalski et al also proved age as an important prognostic factor in T3N0-1 glottic or transglottic cancer \[[@R29]\]. In another study of 945 cases in Sweden, Reizenstein et al reported that elderly laryngeal cancer patients received higher proportion of palliative care rather than radical treatment and thus to have a much higher never-free-from-tumor rate, which might be a potential reason for their increased risk of mortality \[[@R30]\]. In our study, male patients were found to have a significantly greater risk of both overall and cancer-specific mortality compared with female. It has been reported by Shan SJ et al that male head and neck cancer patients were relatively more reluctant to undergo follow-up screening than female \[[@R31]\]. Besides, according to Sharp et al 's research based on a large national cancer database in Ireland, smoking at diagnosis is an independent prognostic factor for cancer-specific survival in head and neck cancer and proportion of current smokers at diagnosis in male patients was much higher than in female \[[@R32]\]. These reasons could partly explain why gender was an independent prognostic and predictive factor for cancer-specific survival. According to our research, marriage demonstrated a significant protective effect, relationship between marital status and cancer outcomes was also certified in many cancer types \[[@R33]--[@R36]\], the role of spousal support in behavior change, psychological regulation and treatment compliance might be potential mechanisms \[[@R37], [@R38]\]. Previous literatures reported that African American people were generally in a lower social class, and possessed worse socioeconomic conditions and living habits, thus to have a higher risk for comorbidities, this could reasonably explain why race was only statistically significantly associated with OS, but not CSS (*P* = 0.160) in the univariate analysis of our study \[[@R39]--[@R43]\]. It's also noteworthy that in the CSS nomogram, N staging had the greatest effect on CSS and in particular, LNR made an even bigger contribution than T categories to both OS and CSS, indicating that nodal status had a stronger influence on prognosis than status of primary tumor, which was in consistence with the opinion by Ferlito et al \[[@R5]\].

Inevitably, potential limitations in our study should be taken into consideration. First, important therapies like chemotherapy were not accessible in SEER database and SEER no longer recorded the type or regions of neck dissection after 2003, besides, extracapsular spread (ECS) as an important prognostic factor for laryngeal cancer patients with positive lymph nodes, wasn't recorded in SEER database as well. Consequently these factors couldn't be recruited in the nomograms. Second, during the 20 years between 1988 and 2008, compared to all the LSCC patients registered in SEER database, those who underwent neck dissection were relatively small (less than 3000), causing a lack of patients in some subgroups, like there were only 20 patients in undifferentiated grade subgroup, which probably reduced accuracy. Third, SEER didn't collect information on some important common-recognized laboratory prognostic indices like SCC-Ag expression, EGFR or VEGF mutation \[[@R44], [@R45]\], they could furtherly improve the predictive performance if incorporated. Fourth, in addition to LNR, positive nodes count and log odds of positive lymph nodes (LODDS) were also potential prognostic indicators provided by neck dissection, further comparisons of their prognostic capabilities were required. Moreover, the nomograms should be validated by prospective research on account of the retrospective nature of our study.

In conclusion, we constructed and validated nomograms estimating overall and cancer-specific survival of laryngeal squamous cell carcinoma patients treated with neck dissection using a large, population-based dataset. These nomograms exhibited high degree of applicability and accuracy, outperforming predictive models in previous literatures as well as TNM staging system. By these predictive tools, it will be more effective to assist clinicians in identifying patients with high risk of mortality and making more precise survival evaluation.

MATERIALS AND METHODS {#s4}
=====================

Data source and inclusion criteria {#s4_1}
----------------------------------

All the data was obtained from Surveillance, Epidemiology, and End Results (SEER) database, which collects information of cancer patients in 18 registries, covering approximately 30% of total U.S population. The database includes some important demographic, diagnostic and treatment information of cancer patients, such as primary sites, morphology, stage, surgery, radiotherapy, grade and patients' vital status. (<http://www.seer.cancer.gov>) SEER\*Stat software (Version 8.3.2) was used to extract information from the database.

The inclusion criteria were as follows: 1) Diagnosed with LSCC as its first and only malignancy. 2) The ICD-O-3 site codes were limited to C32.0 (glottis), C32.1 (supraglottis), C32.2 (subglottis), and C32.8 (overlapping lesion) according to SEER classification. It's worth noting that C32.3 (Laryngeal cartilage) and C32.9 (NOS) were not included because the number of eligible patients was too small (less than 10). 3) Histological type was limited to squamous cell carcinoma (8052, 8070-8078, 8083-8084, 8094, 8560) according to ICD-O-3 histological codes, as appropriate. 4) Underwent neck dissection with definite counts of examined and positive lymph nodes. 5) Diagnosed between 1988 and 2008 to ensure an adequate follow-up length, as the follow-up cutoff date of currently available SEER data was 12/31/2013. 6) Known survival months after diagnosis and known cause of death. 7) Older than 18 years old. 8) Definite information on race, TNM status, grade, surgery, radiotherapy and tumor size. 9) Active follow-up. 10) Excluded if the diagnosis was obtained by death certificate or autopsy only.

Statistical analysis for OS and CSS {#s4_2}
-----------------------------------

The entire group of enrolled patients (*n* = 2752) was randomly divided into a training cohort (*n* = 2477) and a validation cohort (*n* = 275) in order to develop and validate nomograms. Patients' 13 important clinicopathological factors including age at diagnosis, race, gender, marital status, site, grade, TNM status, surgery, radiotherapy, tumor size and lymph node ratio were used to conduct the univariate and multivariate analysis. Optimal cutoffs of tumor size and LNR were determined by X-tile program. Age at diagnosis was grouped by ten years, we combined patients less than 45 years old into one single group because only 15 patients were less than 35, similarly, those older than 75 years old were put into the same group as only 10 individuals in the training cohort were beyond 85.

One of our primary endpoints of interest was OS, defined as the time from diagnosis to death from all possible causes, patients who were alive at the time of last follow-up were counted as censored observations. Kaplan-Meier analysis and log-rank tests were used to identify the significant factors associated with OS. Multivariate Cox proportional hazards models were constructed to analyze the independent effect of significant factors in the univariate log-rank test and present the hazard ratios of different variables.

Another primary endpoint of our interest was CSS, measured as the time from diagnosis to death attributed to LSCC, patients who were alive at the time of last follow-up were counted as censored observations. Cumulative incidence function (CIF) was used to evaluate cancer-specific mortality (CSM) and death resulting from other causes (DROC) which was regarded as competing risks. CIF results of CSM in each subgroup were compared with those calculated by Kaplan-Meier estimates, a Cox regression model was used to conduct multivariate analysis and build a nomogram as it was easy to interpret, compare and comprehend \[[@R25], [@R26]\].

Construction and validation of the nomograms {#s4_3}
--------------------------------------------

Nomograms were constructed based on Cox proportional hazards regression model to predict 3- and 5-year OS and CSS. To minimize the information loss, a backward stepwise method was used to recruit the independent prognostic factors into the construction of the nomograms until the minimal AIC value occurred.

Via the training cohort and the validation cohort, both internal and external nomogram validations were conducted. Performance of these predictive models was assessed by Harrell's concordance-index (C-index), which was similar to area under curve (AUC), but proved to be more suitable for censored data \[[@R46]\]. C-index ranges from 0.5 to 1.0, 0.5 means total chance while 1.0 stands for prefect matching \[[@R12]\]. We also assessed the predictive performance by calibration plot, which was quantified by the comparison between nomogram-predicted survival with observed survival. Bootstraps with 1000 resample were used to conduct these activities \[[@R14]\].

Kaplan-Meier estimates, multivariate Cox regression and log-rank test were analyzed using statistical software IBM SPSS, version 22 (SPSS Inc, Chicago, IL, USA). Cumulative incidence function (CIF), Gray's test, nomogram construction, validation and calibration were performed in R version 3.3.1 (<http://www.r-project.org/>) with *rms* \[[@R47]\] and *cmprsk* \[[@R48]\] packages. All *P* values were two-sided and statistical significance was set at *P* \< 0.05.
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